Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral bosentan added to surfactant for prevention of bronchopulmonary dysplasia in premature infants with respiratory distress syndrome
IRCT20260119068615N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of bosentan in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Severity of respiratory distress at birth, Need for ventilation and 7 more. Started Apr 2026; status: completed.
02
Drugs
bosentan
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on IRCT20260119068615N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260119068615N1.